<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mechanisms of thrombogenesis in atrial fibrillation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mechanisms of thrombogenesis in atrial fibrillation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mechanisms of thrombogenesis in atrial fibrillation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory YH Lip, MD, FRCPE, FESC, FACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrial fibrillation (AF) is associated with substantial mortality and morbidity, largely due to thromboembolism, particularly stroke. This complication can occur with either paroxysmal (intermittent) or chronic (permanent) AF. A number of randomized trials have demonstrated the efficacy of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in reducing this risk both during the course of chronic AF and in the period prior to and after the restoration of sinus rhythm. (See  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a> and  <a class="medical medical_review" href="/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>.)</p><p>The factors that promote thromboembolism in AF will be reviewed here.</p><p class="headingAnchor" id="H2"><span class="h1">FACTORS PROMOTING THROMBOEMBOLISM</span><span class="headingEndMark"> — </span>Almost 150 years ago, Virchow proposed that three conditions should be present for development of thrombosis [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in blood flow</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in the blood vessel wall</p><p class="bulletIndent1"><span class="glyph">●</span>Interaction with blood constituents</p><p></p><p>Each of these abnormalities may contribute to thromboembolism in AF [<a href="#rid2">2,3</a>].</p><p>As an example, dilated atria, poorly contracting dilated left ventricles, valvular heart disease (particularly mitral stenosis), and congestive heart failure are clinical features commonly associated with stroke and thromboembolism in patients with AF [<a href="#rid2">2</a>]. These abnormalities in blood flow and vessels (the first two components of Virchow's triad) can be related to the presence of structural heart disease or extrinsic interventions such as cardioversion. As will be described below, AF also may confer a hypercoagulable or prothrombotic state [<a href="#rid3">3</a>].</p><p>Pooled data from a meta-analysis have demonstrated that independent clinical risk factors for stroke in nonvalvular AF include a history of hypertension and diabetes [<a href="#rid4">4</a>]. Patients with heart failure are also at high risk, particularly those with left ventricular systolic dysfunction or aneurysm formation [<a href="#rid5">5-7</a>]. (See  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p>These clinical criteria are complemented by echocardiographic findings, which have demonstrated that a dilated left atrium, impaired left atrial function, and impaired left ventricular systolic function are independent risk factors for stroke in patients with AF  (<a class="graphic graphic_table graphicRef64291" href="/d/graphic/64291.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef72745" href="/d/graphic/72745.html" rel="external">table 2</a>) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/908.html" rel="external">"Role of echocardiography in atrial fibrillation"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Left atrial abnormalities</span><span class="headingEndMark"> — </span>A dilated left atrium and reduced left atrial and left atrial appendage (LAA) blood flow on echocardiography are independent risk factors for thromboembolism. Patients with these abnormalities are more likely to have stasis of blood as demonstrated by the presence of spontaneous echo contrast or "smoke" on transesophageal echocardiography; this increase in echogenicity is thought to represent aggregation of red cells at low shear stress  (<a class="graphic graphic_diagnosticimage graphicRef66980" href="/d/graphic/66980.html" rel="external">image 1</a> and <a class="graphic graphic_movie graphicRef66795" href="/d/graphic/66795.html" rel="external">movie 1</a> and <a class="graphic graphic_movie graphicRef51472" href="/d/graphic/51472.html" rel="external">movie 2</a>) [<a href="#rid8">8</a>].</p><p>Spontaneous echo contrast has been related to hemodynamic and hemostatic abnormalities and an increased risk of stroke and thromboembolism [<a href="#rid8">8-13</a>]. The presence of both left atrial spontaneous echo contrast and chamber enlargement among patients with nonrheumatic AF is strongly associated with an increased risk for cerebral ischemic events (odds ratio 33.7 in one report) [<a href="#rid11">11</a>]. Left atrial spontaneous echo contrast does not appear to be affected by anticoagulant therapy [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/908.html" rel="external">"Role of echocardiography in atrial fibrillation"</a>.)</p><p>The fibrosis and inflammation seen in the left atrium of patients with AF are particularly intense in the LAA and may predispose to adjacent thrombosis. In addition, the fibrillating LAA is the only area within the left atrium that is comprised of pectinate muscle and can create an appropriate milieu for blood stasis and thrombus formation.</p><p class="headingAnchor" id="H4"><span class="h2">Atrial stunning after cardioversion</span><span class="headingEndMark"> — </span>Cardioversion of AF leads to an increased risk of thromboembolism, particularly if patients are not anticoagulated before, during, and after cardioversion. In addition to dislodgement of pre-existing thrombi, embolization may result from de novo thrombus formation induced by impaired left atrial systolic function. (See  <a class="medical medical_review" href="/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"</a>.)</p><p>The transient atrial contractile dysfunction is also known as atrial "stunning," and can occur whether sinus rhythm is restored spontaneously, by external or internal DC (electric) cardioversion, or by drugs. The duration of the left atrial dysfunction appears to be related in part to the duration of AF. In one report, full recovery of atrial mechanical function was attained within 24 hours in patients with AF for ≤2 weeks, within one week in patients with AF for two to six weeks, and within one month with more prolonged AF [<a href="#rid15">15</a>]. The time course of recovery of left atrial function could explain why the great majority of embolic events in patients who remain in sinus rhythm occur within the first 10 days after cardioversion [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/1041.html" rel="external">"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm", section on 'Atrial stunning'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Paroxysmal atrial fibrillation</span><span class="headingEndMark"> — </span>The risk of thromboembolic events in patients with paroxysmal AF and relationship to AF burden (percentage of time in AF) is discussed separately. (See  <a class="medical medical_review" href="/d/html/956.html" rel="external">"Paroxysmal atrial fibrillation", section on 'Risk of embolization'</a>.)  </p><p>Paroxysmal AF is associated with abnormalities in atrial function, as evidenced by the appearance of spontaneous echo contrast on transesophageal echocardiography [<a href="#rid18">18</a>], and in hemostasis which presumably contribute to the increase in thrombotic risk. One report supported the importance of AF duration as levels of beta-thromboglobulin and platelet factor 4 (markers of platelet activation) were significantly increased during episodes more than 12 hours in duration; there was also a trend toward an elevation in fibrinogen levels in these patients [<a href="#rid19">19</a>]. In another series, patients with paroxysmal AF had intermediate values of fibrinogen and fibrin D-dimer between normals and elevations seen in patients with chronic AF [<a href="#rid20">20</a>]. In contrast, patients with paroxysmal supraventricular tachycardia, who retain active atrial contraction and have a low risk of stroke, had levels of hemostatic markers that were similar to controls in sinus rhythm.</p><p class="headingAnchor" id="H6"><span class="h2">Left ventricular dysfunction</span><span class="headingEndMark"> — </span>Heart failure by itself confers a risk of stroke and thromboembolism; the risk is additive to that of AF [<a href="#rid5">5,7,21</a>]. A report from the SAVE trial, for example, found a progressive increase in stroke risk during a 42-month follow-up in patients with left ventricular dysfunction; furthermore, every 5 percentage point decrease in left ventricular ejection fraction (LVEF) was associated with an 18 percent increase in the risk of stroke [<a href="#rid21">21</a>]. In addition, there was a significant reduction in longitudinal stroke risk associated with the use of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (relative risk 0.19) or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (relative risk 0.44). (See  <a class="medical medical_review" href="/d/html/3502.html" rel="external">"Antithrombotic therapy in patients with heart failure"</a>.)</p><p>Similar findings were noted in a prospective study of 1066 patients entered into three clinical trials evaluating the role of anticoagulation in nonvalvular AF (BAATAF, SPINAF, and SPAF) [<a href="#rid22">22</a>]. The incidence of a stroke was 9.3 percent per year in patients with moderate to severe left ventricular dysfunction, even in the absence of congestive heart failure, compared to 4.4 percent per year in those with normal or mildly abnormal left ventricular function  (<a class="graphic graphic_figure graphicRef70244" href="/d/graphic/70244.html" rel="external">figure 1</a>).</p><p>The presence of a poorly contracting, dilated left ventricle is likely to promote stasis of blood and lead to an increased risk of intracardiac thrombus formation and subsequent embolism. A left ventricular aneurysm has both diastolic and systolic bulging or dyssynergy which result in severe stasis of blood [<a href="#rid5">5</a>]. The incidence of thrombi within left ventricular aneurysms ranges from 14 to 68 percent at postmortem, an observation that is consistent with a 50 to 95 percent incidence at the time of aneurysmectomy [<a href="#rid23">23</a>]. The reported incidence of systemic embolism in patients with a left ventricular aneurysm ranges widely, from 0 to 52 percent [<a href="#rid23">23-26</a>].</p><p>Patients with heart failure, particularly those with a left ventricular aneurysm, also demonstrate abnormalities of blood rheology, coagulation, and endothelial function, suggesting the presence of a prothrombotic or hypercoagulable state. As an example, both plasma fibrinogen and von Willebrand factor concentrations may be elevated in heart failure, and platelet abnormalities are evident [<a href="#rid27">27,28</a>]. Since AF also confers a hypercoagulable state, this may be additive to the hemodynamic and hemostatic abnormalities conferred by heart failure [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Hypertension is a risk factor for stroke (usually thrombotic) and it increases the risk of stroke associated with AF twofold [<a href="#rid2">2,4,6</a>]. How this occurs is unclear. Hypertension may be associated with a hypercoagulable state due in part to abnormalities in blood rheology and endothelial function [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Valvular disease</span><span class="headingEndMark"> — </span>Valvular heart disease, especially mitral stenosis, increases the risk of stroke in AF 17-fold [<a href="#rid31">31</a>]. There is some evidence that the presence of mitral regurgitation is protective against the development of intracardiac thrombi in chronic AF, presumably due to enhanced turbulence and decreased stasis within the left atrium [<a href="#rid5">5</a>]. As an example, one transesophageal echocardiography study of 169 patients with rheumatic heart disease, 63 percent of whom were in AF, found a preoperative incidence of left atrial spontaneous contrast echo of 1, 30, and 54 percent and of thrombus of 1, 13 and 17 percent for those with mitral regurgitation, combined mitral regurgitation and stenosis, and isolated mitral stenosis, respectively [<a href="#rid32">32</a>]. Further support for this observation comes from a report of 32 patients with mitral regurgitation undergoing mitral valve repair; atrial indexes of hypercoagulability were significantly lower than peripheral venous levels, consistent with the clinical observations of reduced echo contrast and left atrial thrombosis [<a href="#rid33">33</a>].</p><p>These findings correlate with a reduced incidence of embolism in mitral regurgitation. The Stroke Prevention in Atrial Fibrillation (SPAF) study, for example, reported that the annual rate of clinical thromboembolism in patients with an enlarged left atrium and abnormal left ventricular wall motion was lower in those with than in those without mitral regurgitation (7.2 versus 15.4 percent) [<a href="#rid34">34</a>]. Chronic mitral regurgitation often leads to left atrial dilatation and dysfunction and associated complications. However, even in the presence of left atrial enlargement, severe mitral regurgitation is associated with a lower incidence of embolism (9 versus 25 percent at 7.4 years in those in whom regurgitation was absent or mild) [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Hypercoagulable state</span><span class="headingEndMark"> — </span>A number of studies that measured indices of coagulability suggest that AF confers a hypercoagulable state, increasing the risk of thromboembolism and stroke [<a href="#rid3">3,12,29,36</a>]. One report of 109 patients with AF fibrillation evaluated the relationship between hemostatic and hemodynamic parameters obtained with transesophageal echocardiography (TEE) and the presence of left atrial thrombus [<a href="#rid12">12</a>]. Compared to patients without evidence of thrombus, those with thrombus had spontaneous echo contrast, reduced LAA velocity, increased plasma concentrations of markers of platelet activation (beta-thromboglobulin and platelet factor 4), increased plasma markers of thrombogenesis (thrombin-antithrombin complexes, D-dimers), and evidence of endothelial damage/dysfunction (elevated plasma and endocardial levels of von Willebrand factor, which is released from damaged endothelium) [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/1532.html" rel="external">"Coronary endothelial dysfunction: Clinical aspects"</a>.) A multiple logistic model identified LAA velocity, beta-thromboglobulin, and von Willebrand factor, but not spontaneous echo contrast, as independent associates of left atrial thromboembolism [<a href="#rid12">12</a>].</p><p>Activation of the coagulation system has been identified in other reports of both paroxysmal [<a href="#rid19">19,20</a>] and chronic AF [<a href="#rid38">38-44</a>]. This effect is independent of the presence or absence of underlying structural heart disease. As noted above, reversion to sinus rhythm results in normalization of hemostatic markers within two to four weeks [<a href="#rid45">45,46</a>].</p><p>Anticoagulation in patients with AF also alters the hypercoagulable state as illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Fibrin D-dimer levels are increased in patients with AF. In one study, fibrin D-dimer levels were highest in patients who were not receiving any antithrombotic therapy, intermediate in those on <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, and lowest in those treated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid41">41</a>]. Similar findings were noted in another report in which patients with AF treated with warfarin had lower levels of prothrombin fragment F1 + 2 and thrombin-antithrombin complex than those treated with aspirin or no antithrombotic therapy [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High fibrin D-dimer levels have been associated with an increased rate of embolic events in patients with AF on oral anticoagulant therapy [<a href="#rid47">47</a>]. In one study, elevated D-dimer levers (≥0.5 mcg/mL) were associated with more thromboembolic events compared to those with low D-dimer levels (hazard ratio 15.8, 95% CI 3.33-75.5) [<a href="#rid48">48</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a substudy from the AFASAK trial, 100 patients with chronic AF were randomized to treatment with fixed minidose <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> 1.25 mg daily alone or in combination with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> 300 mg/day, conventional warfarin therapy with dose adjusted to maintain an International Normalized Ratio (INR) between 2.0 and 3.0 or aspirin 300 mg daily. Patients treated with warfarin at any dose demonstrated a significant rise in the INR with a corresponding reduction in prothrombin fragment F1 + 2 [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The degree of anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> appears to be important. In one report, ultra low-dose warfarin (1 mg/day) did not significantly alter plasma fibrin D-dimer or beta-thromboglobulin levels [<a href="#rid50">50</a>]. A second study found that treatment with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (300 mg daily) plus low-dose warfarin (1 or 2 mg daily) or low-dose warfarin alone (2 mg daily) did not significantly reduce any of the hemostatic markers; in contrast, there was a significant reduction of fibrinogen and fibrin D-dimer with dose-adjusted warfarin [<a href="#rid51">51</a>].</p><p></p><p>Evidence of endothelial damage/dysfunction in AF is provided by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Endocardial damage and disorganization of the LAA endocardium has been described in the setting of mitral valve disease, especially where AF is present [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal plasma indices of endothelial damage/dysfunction, such as vWf, which have been related to thrombogenesis [<a href="#rid41">41</a>], stroke risk [<a href="#rid53">53</a>], and adverse prognosis [<a href="#rid54">54</a>]. (See <a class="local">'Left ventricular dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased levels of circulating endothelial cells (CECs), an index of endothelial damage in the setting of AF and target organ damage (heart failure, stroke, myocardial infarction) [<a href="#rid55">55</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Mechanisms</span><span class="headingEndMark"> — </span>Although these observations suggest that AF is associated with a hypercoagulable state and endothelial dysfunction, the precise mechanisms by which this might occur are uncertain [<a href="#rid3">3,12,56</a>]. Abnormalities in cardiac blood flow (sluggish, slow flow within the atria) may be partly responsible, adding to an endothelial disturbance in the pulmonary vasculature [<a href="#rid41">41,43</a>]. The latter effect may stimulate lung macrophages to produce hepatocyte stimulating factor (now known to be interleukin IL-6), increasing the hepatic synthesis of fibrinogen, perhaps in a similar manner to smoking [<a href="#rid57">57</a>].</p><p>Other data suggest that inflammation may contribute to the hypercoagulable state in AF [<a href="#rid58">58</a>]. As an example, high plasma levels of C-reactive protein (CRP) and interleukin-6 (IL-6) among patients with AF are independently related to indices of the prothrombotic state in AF (eg, CRP to fibrinogen, IL-6 to tissue factor) [<a href="#rid59">59</a>]. CRP has also been related to the presence of dense spontaneous echo contrast (SEC) in the left atrium or LAA on transesophageal echocardiography [<a href="#rid60">60</a>]. SEC is a well-recognized independent predictor for stroke and thromboembolism in AF. Indices of the prothrombotic state and inflammatory markers (IL-6, but not CRP) may predict stroke and vascular events in AF [<a href="#rid54">54,61</a>]. In a larger series of 880 AF patients, CRP was positively correlated to stroke risk and related to stroke risk factors and prognosis (mortality, vascular events) [<a href="#rid62">62</a>].</p><p>Other mechanisms stimulating the prothrombotic state in AF that have been explored include matrix metalloproteinases (MMPs) and their inhibitors (tissue inhibitors of matrix metalloproteinases [TIMPs]) as well as growth factors. In one report, plasma levels of MMP-1 were lower and plasma levels of TIMP-1 were higher in 48 consecutive patients with permanent nonvalvular AF compared with controls [<a href="#rid63">63</a>]. However, these values were not independently associated with the presence of AF on multivariate analysis. Instead, clinical factors (that is, age, ischemic heart disease, or hypertension) and echocardiographic variables (end-diastolic left ventricular diameter or left ventricular mass index) were found to be independently associated with MMP system.</p><p>Abnormal growth factors, such as vascular endothelial growth factor (VEGF, also a marker of angiogenesis) have been related to tissue factor (TF) upregulation — and therefore coagulation — at least in cancer pathophysiology. Among AF patients, TF levels have been shown to be significantly correlated with plasma VEGF levels [<a href="#rid64">64</a>]. In separate studies, plasma levels of TF and VEGF have also been shown to be increased in atherosclerosis, a condition whose pathophysiology involves a tendency to thrombosis and angiogenesis [<a href="#rid65">65,66</a>]. Similar observations have been noted for angiopoietin, another index of angiogenesis [<a href="#rid67">67</a>].</p><p>Other possible mechanisms that have been proposed for the hemostatic abnormalities include neuroendocrine activation [<a href="#rid68">68</a>], slow flow itself [<a href="#rid69">69</a>], increased expression of markers of platelet activation including P-selectin and CD63 [<a href="#rid70">70,71</a>], and elevated serum levels of lipoprotein(a) which is structurally similar to plasminogen and may have antifibrinolytic action [<a href="#rid72">72</a>].</p><p>In a series that included 121 patients with AF, 78 with a history of AF but in sinus rhythm at the time of the study, and 65 control subjects, markers of platelet activation were increased in patients with AF and in those with a history of AF [<a href="#rid71">71</a>]. However, multivariable analysis suggested that the degree of platelet activation was probably due to the underlying cardiovascular diseases associated with AF rather than the AF itself. Indeed, another marker of platelet activation, soluble CD40 ligand levels, was not related to the risk of stroke nor to prognosis [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H29446784"><span class="h3">Prognostic value of elevated biomarkers</span><span class="headingEndMark"> — </span>Measures of the prothrombotic state in patients with AF, using biomarkers such as von Willebrand factor (vWF) or D-dimer (both of which are discussed in the section above), have been evaluated for their prognostic value. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Fibrin D-dimer'</a>.)</p><p>With regard to vWF, the following observations have been made:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 1321 patients with AF, there was a significant stepwise increase in plasma vWf levels as the risk of stroke increased [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two studies have suggested that the addition of plasma vWf levels to traditional risk predictors may improve the ability to predict stroke and vascular events [<a href="#rid54">54,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 229 patients with permanent AF who were stabilized on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy for at least six months, high plasma vWF levels (&gt;221 international units/dl) were an independent predictor for adverse events, including death, stroke, and bleeding during two years of follow-up [<a href="#rid74">74</a>].</p><p></p><p>Two studies have found that D-dimer levels added to the ability of traditional risk factors to predict adverse outcomes [<a href="#rid47">47,48</a>], while one did not [<a href="#rid74">74</a>]. </p><p>Other biomarkers have been tested in highly selected clinical trial cohorts to predict the risk of stroke, thromboembolism, or bleeding. These have included troponin, natriuretic peptides, and growth differential factor 15 (GDF15) [<a href="#rid75">75-77</a>]. These have led to proposals of biomarker-based stroke and bleeding risk scores, ABC-stroke, and ABC-bleeding, respectively [<a href="#rid78">78</a>]. In the real world clinical setting, the ABC-stroke and ABC-bleeding scores did not offer any advantage over clinical factor-based scores, such as CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED [<a href="#rid79">79,80</a>]. Also, the small incremental value of improved prediction of high risk (at least statistically) should be balanced against the simplicity and practicality for everyday clinical use [<a href="#rid78">78</a>].  </p><p>In another study, addition of multiple biomarkers enhanced the predictive value of CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED, although the overall improvement was modest, the added predictive advantage over original scores was marginal, and decision curve analyses found lower net benefit compared with the original clinical scores [<a href="#rid81">81</a>].</p><p>Many of these biomarkers are predictive of thromboembolism, bleeding, death, heart failure, and hospitalizations, as well as noncardiovascular conditions, such as glaucoma progression. This may lead to confusion amongst clinicians over which end point to focus on.</p><p class="headingAnchor" id="H83790729"><span class="h2">Use of indices of a prothrombotic or hypercoagulable state to test anticoagulation therapies</span><span class="headingEndMark"> — </span>Indices such as fibrin D-dimer are indicative of a prothrombotic state in AF. They have been used as biomarker surrogates of thrombogenesis in AF when testing anticoagulation regimes in Phase 2 clinical trials and to help with dose selection for large Phase 3 clinical trials [<a href="#rid82">82-85</a>].</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>The mechanisms leading to an increased risk of stroke, thrombus, and embolism in atrial fibrillation (AF) are multiple, complex, and closely interact with each other. Many of these factors can be explained by Virchow's triad for thrombogenesis. Consideration must be given to the patient's age, the presence of structural heart disease, and clinical risk factors such as previous hypertension, diabetes, various biomarkers, or heart failure (particularly depressed left ventricular systolic function). In addition, AF appears to be associated with a reversible hypercoagulable state, which complements the clinical and echocardiographic features in explaining the mechanisms of thrombosis in this common disorder.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medizin, Medinger Sohn &amp; Co, Frankfurt 1856. p.219.</li><li><a class="nounderline abstract_t">Lip GY, Lowe GD. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ 1996; 312:45.</a></li><li><a class="nounderline abstract_t">Lip GY. Does atrial fibrillation confer a hypercoagulable state? Lancet 1995; 346:1313.</a></li><li><a class="nounderline abstract_t">Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449.</a></li><li><a class="nounderline abstract_t">Lip GY. Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgrad Med J 1996; 72:731.</a></li><li><a class="nounderline abstract_t">Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116:1.</a></li><li><a class="nounderline abstract_t">Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992; 116:6.</a></li><li><a class="nounderline abstract_t">Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18:398.</a></li><li><a class="nounderline abstract_t">Daniel WG, Nellessen U, Schröder E, et al. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol 1988; 11:1204.</a></li><li><a class="nounderline abstract_t">Black IW, Chesterman CN, Hopkins AP, et al. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993; 21:451.</a></li><li><a class="nounderline abstract_t">Jones EF, Calafiore P, McNeil JJ, et al. Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke. Am J Cardiol 1996; 78:425.</a></li><li><a class="nounderline abstract_t">Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77:407.</a></li><li><a class="nounderline abstract_t">Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol 2005; 45:1807.</a></li><li><a class="nounderline abstract_t">Tsai LM, Chen JH, Lin LJ, Teng JK. Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation. Am J Cardiol 1997; 80:897.</a></li><li><a class="nounderline abstract_t">Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23:1535.</a></li><li><a class="nounderline abstract_t">Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol 1998; 82:1545.</a></li><li><a class="nounderline abstract_t">Gentile F, Elhendy A, Khandheria BK, et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc 2002; 77:897.</a></li><li><a class="nounderline abstract_t">Obarski TP, Salcedo EE, Castle LW, Stewart WJ. Spontaneous echo contrast in the left atrium during paroxysmal atrial fibrillation. Am Heart J 1990; 120:988.</a></li><li><a class="nounderline abstract_t">Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29:106.</a></li><li><a class="nounderline abstract_t">Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 1996; 131:724.</a></li><li><a class="nounderline abstract_t">Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336:251.</a></li><li><a class="nounderline abstract_t">Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158:1316.</a></li><li><a class="nounderline abstract_t">Nixon JV. Left ventricular mural thrombus. Arch Intern Med 1983; 143:1567.</a></li><li><a class="nounderline abstract_t">Lapeyre AC 3rd, Steele PM, Kazmier FJ, et al. Systemic embolism in chronic left ventricular aneurysm: incidence and the role of anticoagulation. J Am Coll Cardiol 1985; 6:534.</a></li><li><a class="nounderline abstract_t">Mullen DC, Posey L, Gabriel R, et al. Prognostic considerations in the management of left ventricular aneurysms. Ann Thorac Surg 1977; 23:455.</a></li><li><a class="nounderline abstract_t">SCHLICHTER J, HELLERSTEIN HK, KATZ LN. Aneurysm of the heart: a correlative study of one hundred and two proved cases. Medicine (Baltimore) 1954; 33:43.</a></li><li><a class="nounderline abstract_t">Lip GY, Lowe GD, Metcalfe MJ, et al. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995; 76:453.</a></li><li><a class="nounderline abstract_t">Chung I, Lip GY. Platelets and heart failure. Eur Heart J 2006; 27:2623.</a></li><li><a class="nounderline abstract_t">Lip GY. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation. Heart 1997; 77:395.</a></li><li><a class="nounderline abstract_t">Lip GY, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8:693.</a></li><li><a class="nounderline abstract_t">Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28:973.</a></li><li><a class="nounderline abstract_t">Ozkan M, Kaymaz C, Kirma C, et al. Predictors of left atrial thrombus and spontaneous echo contrast in rheumatic valve disease before and after mitral valve replacement. Am J Cardiol 1998; 82:1066.</a></li><li><a class="nounderline abstract_t">Goldsmith IR, Blann AD, Patel RL, Lip GY. Reduced indexes of left atrial hypercoagulability in patients with severe mitral regurgitation. Am J Cardiol 2000; 86:234.</a></li><li><a class="nounderline abstract_t">Blackshear JL, Pearce LA, Asinger RW, et al. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol 1993; 72:840.</a></li><li><a class="nounderline abstract_t">Nakagami H, Yamamoto K, Ikeda U, et al. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J 1998; 136:528.</a></li><li><a class="nounderline abstract_t">Feng D, D'Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol 2001; 87:168.</a></li><li><a class="nounderline abstract_t">Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001; 37:1436.</a></li><li><a class="nounderline abstract_t">O'Neill PG, Puleo PR, Bolli R, Rokey R. Return of atrial mechanical function following electrical conversion of atrial dysrhythmias. Am Heart J 1990; 120:353.</a></li><li><a class="nounderline abstract_t">Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16:377.</a></li><li><a class="nounderline abstract_t">Gustafsson C, Blombäck M, Britton M, et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21:47.</a></li><li><a class="nounderline abstract_t">Lip GY, Lowe GD, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73:527.</a></li><li><a class="nounderline abstract_t">Asakura H, Hifumi S, Jokaji H, et al. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis 1992; 3:469.</a></li><li><a class="nounderline abstract_t">Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34:255.</a></li><li><a class="nounderline abstract_t">Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) 1995; 89:205.</a></li><li><a class="nounderline abstract_t">Lip GY, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol 1995; 51:245.</a></li><li><a class="nounderline abstract_t">Abe, Y, Kim, et al. Evidence for the intravascular hyperclotting state induced by atrial fibrillation itself (abstract). J Am Coll Cardiol 1996; 27(Suppl A):35A.</a></li><li><a class="nounderline abstract_t">Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90:1163.</a></li><li><a class="nounderline abstract_t">Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55:2225.</a></li><li><a class="nounderline abstract_t">Petersen P, Kastrup J, Helweg-Larsen S, et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Arch Intern Med 1990; 150:819.</a></li><li><a class="nounderline abstract_t">Lip GY, Lip PL, Zarifis J, et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94:425.</a></li><li><a class="nounderline abstract_t">Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31:828.</a></li><li><a class="nounderline abstract_t">Goldsmith I, Kumar P, Carter P, et al. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000; 140:777.</a></li><li><a class="nounderline abstract_t">Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106:1962.</a></li><li><a class="nounderline abstract_t">Conway DS, Pearce LA, Chin BS, et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003; 107:3141.</a></li><li><a class="nounderline abstract_t">Freestone B, Lip GY, Chong AY, et al. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost 2005; 94:702.</a></li><li><a class="nounderline abstract_t">Lip GY. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet 1997; 349:1565.</a></li><li><a class="nounderline abstract_t">Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci U S A 1982; 79:1530.</a></li><li><a class="nounderline abstract_t">Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27:136.</a></li><li><a class="nounderline abstract_t">Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004; 43:2075.</a></li><li><a class="nounderline abstract_t">Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004; 93:1368.</a></li><li><a class="nounderline abstract_t">Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148:462.</a></li><li><a class="nounderline abstract_t">Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007; 38:1229.</a></li><li><a class="nounderline abstract_t">Marín F, Roldán V, Climent V, et al. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34:1181.</a></li><li><a class="nounderline abstract_t">Chung NA, Belgore F, Li-Saw-Hee FL, et al. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 2002; 33:2187.</a></li><li><a class="nounderline abstract_t">Blann AD, Belgore FM, McCollum CN, et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002; 102:187.</a></li><li><a class="nounderline abstract_t">Makin AJ, Chung NA, Silverman SH, Lip GY. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci (Lond) 2003; 104:397.</a></li><li><a class="nounderline abstract_t">Freestone B, Chong AY, Lim HS, et al. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med 2005; 37:365.</a></li><li><a class="nounderline abstract_t">Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127:607.</a></li><li><a class="nounderline abstract_t">Lip GY, Lowe GD, Metcalfe MJ, et al. Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease. Int J Cardiol 1995; 50:31.</a></li><li><a class="nounderline abstract_t">Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998; 98:1721.</a></li><li><a class="nounderline abstract_t">Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007; 49:1957.</a></li><li><a class="nounderline abstract_t">Igarashi Y, Yamaura M, Ito M, et al. Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study. Am Heart J 1998; 136:965.</a></li><li><a class="nounderline abstract_t">Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37:2294.</a></li><li><a class="nounderline abstract_t">Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57:2496.</a></li><li><a class="nounderline abstract_t">Hijazi Z, Siegbahn A, Andersson U, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014; 129:625.</a></li><li><a class="nounderline abstract_t">Hijazi Z, Wallentin L, Siegbahn A, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 2014; 63:52.</a></li><li><a class="nounderline abstract_t">Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013; 61:2274.</a></li><li><a class="nounderline abstract_t">Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013; 34:1041.</a></li><li><a class="nounderline abstract_t">Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, et al. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost 2017; 117:1848.</a></li><li><a class="nounderline abstract_t">Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores. J Am Heart Assoc 2017; 6.</a></li><li><a class="nounderline abstract_t">Roldán V, Rivera-Caravaca JM, Shantsila A, et al. Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers. Ann Med 2018; 50:26.</a></li><li><a class="nounderline abstract_t">Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30:2897.</a></li><li><a class="nounderline abstract_t">Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104:633.</a></li><li><a class="nounderline abstract_t">Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 2013; 34:1498.</a></li><li><a class="nounderline abstract_t">Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100:1419.</a></li></ol></div><div id="topicVersionRevision">Topic 981 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medizin, Medinger Sohn &amp; Co, Frankfurt 1856. p.219.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555864" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475767" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Does atrial fibrillation confer a hypercoagulable state?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018000" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9015466" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727091" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727097" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1856407" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2966840" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8426010" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8752187" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Atrial fibrillation with left atrial spontaneous contrast detected by transesophageal echocardiography is a potent risk factor for stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196408" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15936610" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382005" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8195510" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874066" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233921" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety of electrical cardioversion in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220555" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Spontaneous echo contrast in the left atrium during paroxysmal atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996302" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8721646" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995087" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ventricular dysfunction and the risk of stroke after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9645825" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6347112" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Left ventricular mural thrombus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4031266" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Systemic embolism in chronic left ventricular aneurysm: incidence and the role of anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/856081" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prognostic considerations in the management of left ventricular aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13132257" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aneurysm of the heart: a correlative study of one hundred and two proved cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7653443" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17028108" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Platelets and heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196404" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807500" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Abnormalities of rheology and coagulation in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/570666" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817483" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Predictors of left atrial thrombus and spontaneous echo contrast in rheumatic valve disease before and after mitral valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10913493" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reduced indexes of left atrial hypercoagulability in patients with severe mitral regurgitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213525" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9736148" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11152833" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hemostatic state and atrial fibrillation (the Framingham Offspring Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11300458" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2382612" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Return of atrial mechanical function following electrical conversion of atrial dysrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2373815" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Increased intracardiovascular clotting in patients with chronic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2105543" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7626351" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1420823" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205537" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7493413" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fibrin D-dimer: a useful clinical marker of thrombogenesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8586473" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Evidence for the intravascular hyperclotting state induced by atrial fibrillation itself (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14652652" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466203" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2183733" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759084" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10753983" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054625" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370220" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796127" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16270620" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174554" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6461860" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278230" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Is atrial fibrillation an inflammatory disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15172416" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15165916" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389233" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332453" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663879" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12215585" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834138" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12653684" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16179272" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8122609" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7558462" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a prothrombotic state in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9788825" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17498581" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9842008" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16888271" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21497043" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24226808" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24055845" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23563134" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23257951" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28799620" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28729407" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28892413" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA2DS2-VASc and HAS-BLED scores using multiple biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690349" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20694273" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23487517" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17950801" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
